Landscape Capital Management L.L.C. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Landscape Capital Management L.L.C. purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,513 shares of the company’s stock, valued at approximately $585,000.

Several other institutional investors also recently bought and sold shares of AXSM. Russell Investments Group Ltd. lifted its stake in shares of Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after buying an additional 777 shares in the last quarter. Vanguard Group Inc. boosted its stake in Axsome Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock valued at $298,474,000 after purchasing an additional 43,512 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in shares of Axsome Therapeutics by 136.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,370 shares of the company’s stock worth $588,000 after purchasing an additional 4,258 shares in the last quarter. Natixis raised its stake in shares of Axsome Therapeutics by 13.6% in the first quarter. Natixis now owns 1,235 shares of the company’s stock worth $99,000 after purchasing an additional 148 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of Axsome Therapeutics during the first quarter valued at $35,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total value of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. The trade was a 52.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Up 0.5 %

AXSM stock opened at $98.68 on Friday. The business’s 50-day moving average price is $90.99 and its 200-day moving average price is $85.01. The stock has a market cap of $4.78 billion, a P/E ratio of -15.11 and a beta of 1.26. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a twelve month low of $60.28 and a twelve month high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.38) by $0.04. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm earned ($1.32) earnings per share. On average, equities research analysts forecast that Axsome Therapeutics, Inc. will post -4.75 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AXSM shares. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They set an “overweight” rating and a $140.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $130.00 target price on shares of Axsome Therapeutics in a report on Tuesday, November 12th. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price target on shares of Axsome Therapeutics in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.93.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.